329 related articles for article (PubMed ID: 33051960)
1. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
2. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
[TBL] [Abstract][Full Text] [Related]
3. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
Saleh MA; Saleh NA
Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
[TBL] [Abstract][Full Text] [Related]
4. Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.
Jafri ZA; Walia S; Ivanic MG; Wu JJ
J Dermatolog Treat; 2022 May; 33(3):1606-1607. PubMed ID: 33375865
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
Róbert L; Kovács A; Sárdy M; Fábián M
Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
[TBL] [Abstract][Full Text] [Related]
6. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
7. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
9. Future therapies for pemphigus vulgaris: Rituximab and beyond.
Huang A; Madan RK; Levitt J
J Am Acad Dermatol; 2016 Apr; 74(4):746-53. PubMed ID: 26792592
[TBL] [Abstract][Full Text] [Related]
10. Rituximab Therapy for Childhood Pemphigus Vulgaris.
Kincaid L; Weinstein M
Pediatr Dermatol; 2016; 33(2):e61-4. PubMed ID: 26765543
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.
Özgen Z; Aksoy H; Akın Çakıcı Ö; Koku Aksu AE; Erdem O; Kara Polat A; Gürel MS
Dermatol Ther; 2022 May; 35(5):e15417. PubMed ID: 35243732
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
[TBL] [Abstract][Full Text] [Related]
14. Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab.
Waldman RA; Creed M; Sharp K; Adalsteinsson J; Imitola J; Durso T; Lu J
J Am Acad Dermatol; 2021 Apr; 84(4):e197-e198. PubMed ID: 33130180
[No Abstract] [Full Text] [Related]
15. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
16. COVID outcome in pemphigus: Does rituximab make pemphigus patients susceptible to more severe COVID-19?
Aryanian Z; Balighi K; Sajad B; Esmaeli N; Daneshpazhooh M; Mazloumi Tootoonchi N; Beigmohammadi F; Mohseni Afshar Z; Hatami P
J Cosmet Dermatol; 2023 Nov; 22(11):2880-2888. PubMed ID: 37573477
[TBL] [Abstract][Full Text] [Related]
17. Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature.
Mistry BD; Leis M; Lee DM; Levy R
Pediatr Dermatol; 2022 Nov; 39(6):960-966. PubMed ID: 35871636
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
19. Resolution of a case of pediatric pemphigus vulgaris treated with rituximab.
Didona D; Paolino G; Donati M; Caposeina D; Calvieri S; Didona B
Acta Dermatovenerol Croat; 2014; 22(4):288-90. PubMed ID: 25580789
[TBL] [Abstract][Full Text] [Related]
20. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
Greenblatt DT; Benton EC; Groves RW; Setterfield JF
Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]